NCT03146156Completed
Lifestyle Intervention in Preparation for Pregnancy (LIPP)
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
Studies evaluating lifestyle intervention in obese women during pregnancy have reported limited success in decreasing excessive gestational weight gain, and have failed to achieve the key outcome of breaking the obesity cycle and reducing neonatal adiposity or birth weight. Although some investigators advocate weight loss during pregnancy in obese women, these recommendations were based on extrapolation of retrospective epidemiological data. Of concern, we reported increased small for gestational age babies and decreased lean body mass in neonates of obese women with weight loss or inadequate gestational weight gain. Based on our research, optimal outcomes from lifestyle interventions are likely to be temporal and therefore must be initiated prior to conception to first improve maternal metabolic function, and subsequently, placental/fetal growth. Several large retrospective cohort studies support our hypothesis. For example, women who lost weight between pregnancies had fewer large for gestational age babies in contrast to women who increased interpregnancy weight. In addition, prospective randomized controlled trials have shown that postpartum weight loss is achievable without adverse maternal or neonatal outcomes, these studies include women who breastfed. Based on these observations, we propose a randomized control trial to determine the effect of lifestyle intervention initiated prior to a planned pregnancy on improving neonatal metabolism and adiposity. Our overarching hypothesis is that the maternal pre-pregnancy metabolic condition determines the obesogenic in-utero environment, which affects programming of placental mitochondrial function and metabolic pathways, promoting lipid accumulation and neonatal adiposity. Our rationale is based on the need to establish the most effective time to introduce an intervention that will break the obesity cycle in mothers and their children. Understanding how pregravid metabolic conditioning improves maternal physiology, and cellular and molecular function in pregnancy will provide the empirical data to support the intervention. We have a highly successful record of recruiting women who are planning a pregnancy, obtaining compliance in longitudinal studies, and in long-term follow-up of mothers and their offspring. Lifestyle intervention will be initiated prior to conception to decrease maternal body fat, inflammation, insulin resistance, and ?-cell dysfunction. Our transdisciplinary team has the required expertise in lifestyle interventions management of obesity, and in human physiology that is needed to determine the effects of these interventions on maternal metabolism and fetalplacental growth and function. We will recruit 200 women to pursue the following specific aims: Specific Aim 1: To investigate the physiological significance of lifestyle intervention in preparation for pregnancy (LIPP) on maternal and neonatal metabolism and adiposity. Specific Aim 2: To determine the molecular effects whereby lifestyle intervention initiated before pregnancy can improve placental mitochondrial lipid oxidation and accumulation.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 143 (actual)
- First submitted
- 22 Mar 2017
- Start date
- 21 Mar 2017
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Tufts Medical Center
- Diseases
- Obesity
- NCT number
- NCT03146156
What you commit to
- Study type: Interventional
- Participants enrolled: 143
- From 21 Mar 2017 to the primary completion date, 31 Aug 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- asthma requiring more than occasional use of a sympathomimetic inhaler, but not chronic inhaled steroids
- Tobacco, excessive alcohol use (greater than 2 drinks/day) or illicit drug use
- Gastric surgery to lose weight including banding or bypass procedures
- If a LIPP subject becomes pregnant prior to 16 weeks after randomization before the weight- loss phase for the lifestyle intervention is completed or a control subject becomes pregnant before the 3 month postpartum randomization, i.e. no baseline measurement.
Other illness
- Pre or post-delivery diabetes
- Post-delivery hypertension requiring medication
- Inflammatory bowel disease
- Eating disorders such as bulimia
- Any psychological or psychiatric condition which may impair participation in the lifestyle intervention program
- HIV, or hepatitis B or C
Other
- Need for assisted reproductive technologies to become pregnant
- Medical or obstetrical contraindication to the defined exercise program or diet
- Multiple pregnancy
Who the study is looking for
- All subjects will have had by the time of randomization at 3 months postpartum:
- Planning another pregnancy within the next 24 months
- Planning to deliver at Tufts medical center during their next pregnancy
- A previous full-term singleton pregnancy (gestational age \> 37 weeks)
- 18 to 40 years of age at the time of enrollment into the study
- Vaginal or cesarean delivery
- Normal glucose tolerance or gestational diabetes (GDM), but without evidence of postpartum diabetes as defined by a 75 g 2-hr oral glucose tolerance test (OGTT)
- Normal blood pressure or mild preeclampsia but normal postpartum blood pressure
- Bottle or breast feeding
- Normal thyroid function (determined by TSH concentration in blood), normal cell blood count and normal kidney and liver functions. Lipid profile with triglyceride levels not higher than 400 mg/dl (fasting) and LDL levels less than 180 mg/dL
- No clinical signs or symptoms of cardiovascular disease or any other disease or condition that may contraindicate participation in exercise training (i.e. COPD, severe asthma, orthopedic abnormalities)
- Using contraception
Age in the registry: 18 years to 40 years · Sex: Female · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pennington Biomedical Research Center Coordinator of this site? Confirm its status | Baton Rouge | United States | Unknown status |
| Tufts Medical Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| MetroHealth Medical Center Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.